| Institution: | (1) Novartis Pharmaceuticals Corp., 59 Route 10, East Hanover, New Jersey, 07936;(2) P'Kinetics, Inc., Miami, Florida;(3) Center of Drug Evaluation & Research, FDA, Rockville, Maryland;(4) Hercon Laboratory Corp., Emigsville, Pennsylvania;(5) Elan Corporation, Athlone, Ireland;(6) 3M Pharmaceuticals, St. Paul, Minnesota;(7) Cygnus Inc., Redwood City, California;(8) University of Maryland, Baltimore, Maryland;(9) University of Michigan, Ann Arbor, Michigan;(10) University of Kentucky, Lexington, Kentucky;(11) Alza Corp., Palo Alto, California;(12) Novartis Pharmaceuticals Corp., Suffern, New York;(13) Theratec, Inc, Salt Lake City, Utah;(14) Novartis Pharmaceuticals Corp., Suffern, New York;(15) Bertek, Inc., St. Albans, Vermont;(16) USP, Rockville, Maryland;(17) 3M Pharmaceuticals, St. Paul, Minnesota;(18) Center of Drug Evaluation & Research, FDA, Rockville, Maryland;(19) Cygnus Inc., Redwood City, California;(20) Schering Laboratories, Miami Lakes, Florida;(21) Noven Pharmaceuticals, Miami, Florida;(22) Pharmaco International, Richmond, Virginia;(23) Alza Corp., Palo Alto, California;(24) Lohmann Therapeutic Systems, West Caldwell, New Jersey |
